Skip to main content
. 2021 Dec 5;16:233. doi: 10.1186/s13014-021-01955-7

Table 3.

Incidence of AEs

Treatment-related AEs, n (%) Osimertinib group
(n = 40)
Osimertinib + RT group
(n = 21)
P
Any grade 13 (32.5) 10 (47.6) 0.762
Fatigue 1 (2.5) 0 (0)
Rash 5 (12.5) 1 (4.7)
Diarrhea 3 (7.5) 1 (4.7)
Myocardial damage 2 (5.0) 0 (0)
Pneumonitis 3 (7.5) 0 (0)
Oral ulcer 0 (0) 1 (4.7)
Leukoencephalopathy 0 (0) 6 (28.5)
Neutrophil count decreased 6 (15.0) 3 (14.2)
Grade ≥ 3 3 (7.5) 4 (19.0) 0.220
Neutrophil count decreased 3 (7.5) 1 (4.7)
Leukoencephalopathy 0 3 (14.2)

RT cranial radiotherapy